A new article was published in CPT: Pharmacometrics & Systems Pharmacology

Sokolov V, Yakovleva T, Chu L, Tang W, Greasley PJ, Johansson S, Peskov K, Helmlinger G, Boulton DW, Penland RC. Differentiating the Sodium-Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling. CPT Pharmacometrics Syst Pharmacol. 2020 Feb 16. doi: 10.1002/psp4.12498

This manuscript describes an application of the previously published QSP model (Yakovleva T et al., Diabetes Obes Metab (2019) 21, 2684-2693) to the differentiation of the clinical effects observed for the gliflozins, currently available on the market based on their capacity to inhibit sodium-glucose cotransporter (SGLT) 1 and 2 in patients with type 2 diabetes.